Is Leqembi's approval a game-changer for Alzheimer's?
On 6th July 2023, the FDA granted full approval to Leqembi, an Alzheimer's drug developed by Japanese pharmaceutical company Eisai and its U.S. partner Biogen. The approval comes amidst safety and cost concerns surrounding the drug.
Delve into this significant development and gain expert insights on the approval process and its implications.
?? Expert Opinions:
?? "It's not something that's going to stop the disease or reverse it, but it may slow down the progression of the disease and may give people more meaningful time with their families. It's very exciting that we're targeting the actual pathology of the disease. I think patients are a little wary because they hear about bleeding or swelling in the brain. They are concerned, and I think rightfully so." - Sanjeev Vaishnavi - Director of Clinical Research at the Penn Memory Center
?? “This treatment, while not a cure, can give people in the early stages of Alzheimer’s more time to maintain their independence and do the things they love. This gives people more months of recognizing their spouse, children, and grandchildren. This also means more time for a person to drive safely, accurately, and promptly take care of family finances, and participate fully in hobbies and interests.” - Joanne Pike - President and CEO of the Alzheimer's Association
领英推荐
?? “Today’s action is the first verification that a drug targeting the underlying disease process of Alzheimer’s disease has shown clinical benefit in this devastating disease. This confirmatory study verified that it is a safe and effective treatment for patients with Alzheimer’s disease.” - Teresa Buracchio - Acting Director of the Office of Neuroscience in the FDA’s Center for Drug Evaluation and Research
PharmaScroll’s KOL database, TreasureTell, provides insights into KOLs’ opinions on drug developments, clinical trials, and other healthcare industry advancements. TreasureTell also provides insights on KOLs’ clinical trial involvements, publications, latest engagements, and much more.
To learn more about TreasureTell visit: www.pharmascroll.com
Request a demo: [email protected]